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Abstract
Objective To describe access to antiepileptic drug therapy and estimate the preva-
lence of epilepsy in children in Camagüey Province, Cuba.
Methods All the community pharmacies in the province were visited and informa-
tion collected about the number of children receiving antiepileptic drugs in 2009.
Availability and cost of each antiepileptic drug were determined. The prevalence
of epilepsy was estimated by determining the number of children receiving anti-
epileptic drugs.
Results There were 923 children who received a total of 977 antiepileptic drugs
in Camagüey Province. The estimated prevalence of epilepsy was 5.18 per thousand
children which is lower than previously reported rates in other low and lower-
middle income countries. Most of the children (871, 94%) received a single antiepi-
leptic drug. Carbamazepine and valproate were the two most frequently prescribed
antiepileptic drugs. Antiepileptic drugs were available from the local pharmacy on
76% of occasions. If the antiepileptic drug was not available from the local phar-
macy, the parent had to travel to another pharmacy to obtain the medicine.
Conclusions The estimated prevalence of epilepsy in children in Cuba is lower than
that estimated in other lower-middle income countries. Access to drug therapy in
children with epilepsy can be achieved in lower-middle income countries.
Introduction
Epilepsy is one of the most common neurological conditions
affecting children worldwide. The prevalence of epilepsy in
children ranges from 1.5–8 per thousand children. Most of
these studies have been conducted in high-income coun-
tries.[1,2] The prevalence of epilepsy in Latin America and the
Caribbean has been less extensively studied, but appears to be
higher (8.7–12.4 per thousand).[3,4] The prevalence of epilepsy
in children in Cuba at present is unknown.
It has been estimated that worldwide 80–85% of individu-
als with epilepsy fail to receive treatment.[5–8] There are many
possible reasons for this. The individual may not have seen
a health professional to diagnose the epilepsy or the anti-
epileptic drug (AED) is too expensive or not readily avai-
lable. Several AEDs (carbamazepine, diazepam, lorazepam,
phenobarbital, phenytoin and sodium valproate) are on
the World Health Organization’s List of Essential Medicines
for Children.[9] The presence/absence of essential medicines
for children in pharmacies has been used as a marker of the
availability of essential medicines.[10]
Cuba, despite being a poor country, has an excellent health-
care system.[11] Its under-5 child mortality rate is comparable
to that of high-income countries. Its success is thought to be
due to two main factors: (1) an excellent primary healthcare
system and (2) universal access to free health care.[11]
A National Medicines Programme involving family doctors
and pharmacists was established in Cuba in 1991 to ensure the
availability of essential medicines for all patients.[12] Since
1994, patients with epilepsy are registered.[12] Following the
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diagnosis of epilepsy by the provincial paediatric neurology
teamattheProvincialChildren’sHospital inCamagüey,Cuba,
parents receive a medical certificate. This certificate states the
diagnosis, the AED that the patient is to receive, the dose and
duration of treatment (maximum of 1 year,as all children with
epilepsy are reviewed at least once a year by the provincial
paediatric neurology team). Subsequently, the parents can
present their certificate at a community pharmacy in order
to purchase the AED for their child without the need for a
further prescription.
There are three types of community pharmacies in
Cuba. Each municipality (and each of the four districts in
Camagüey Municipality) has a main pharmacy. The next level
of pharmacy is the special pharmacy which is usually located
next to a polyclinic. The number of special pharmacies in
each municipality/district ranges from zero to five. The third
level of pharmacy is a local pharmacy. These are usually
located in isolated or rural communities and have the small-
est stock of drugs. The number of local pharmacies within
each municipality/district ranges from one to 14. The cost
of any medicine is identical at all community pharmacies
throughout the country. Like other medicines in Cuba, AEDs
need to be purchased at a minimal cost. Topiramate and two
formulations of sodium valproate (tablet or a suspension of
200 mg/5 ml) are not available at community pharmacies.
They are only available from the hospital pharmacy and
because parents have to travel to the hospital pharmacy to
obtain these medicines, they are dispensed free of charge.
Access to drug therapy is a key component of health care
and we therefore decided to look at access to AED therapy for
children with epilepsy in Camagüey Province. The primary
supplier for AEDs is the community pharmacy.
Methods
Setting
An observational study was conducted between January and
December 2009 in the Province of Camagüey. Camagüey is
the largest province of the island in Cuba and is located in the
central region. It is divided into 13 municipalities and the
main municipality of Camagüey is subdivided into four
districts. Each municipality has urban and rural areas and
in 2009 the province had a population of 178 231 children
under the age of 18 years. Camagüey Province has 149 com-
munity pharmacies. These include 16 main pharmacies,
31 special pharmacies and 102 local pharmacies. The area
covered by each individual pharmacy can vary considerably.
In urban areas pharmacies cover an average area of 20 km2.
In rural areas they cover a larger area (up to a maximum of
200 km2). Distances between pharmacies range from 20 m in
an urban setting near a hospital (the minimum) and 50 km in
rural areas.
Data collection
Each individual community pharmacy has a Pharmacy
Technical Director. This individual obtained data regarding
the availability of each AED throughout the study period.
Further information regarding stock and availability of
each AED was obtained by telephone at the end of February,
June and December 2009. Additionally, each of the 149 com-
munity pharmacies in the province was visited by one of the
researchers on one occasion during the first 6 months of
the year.
Data
Medical certificates for patients receiving AEDs were
reviewed at each individual community pharmacy. Certifi-
cates for patients under 18 years with a diagnosis of any type
of epilepsy were retrieved and data regarding age, type of
AEDs received and doses were collected and entered onto a
secure electronic database with restricted access.
Information about patients attending pharmacies was
crosschecked with the patient data stored in paper-based
records at the paediatric neurology clinic at Camagüey
Children’s Hospital. Monthly data were collected and cross-
checked from the hospital by the research team. The price
for AEDs was taken from the ‘National Official Prices List to
the Population’ produced by the Cuban government, and the
monthly cost of treatment for children was calculated.
Results
There were 923 children with epilepsy receiving a total of 977
AEDs identified. This is a prevalence of 5.18 per thousand
children. Eight hundred and seventy-one children were on
monotherapy, 50 on two AEDs and two on three AEDs. The
age distribution of the children with epilepsy and the preva-
lence in relation to age is shown in Table 1. Crosschecking
identified five children who had attended the paediatric
neurology clinic but had not registered with a community
pharmacy. These children were initially receiving AEDs from
Table 1 Age and prevalence of children with epilepsy in Camagüey
Province, Cuba
Age of
children
Number of
children
with epilepsy
Number of
children
in province
Prevalence of
epilepsy per
1000 children
0–11 months 4 8 387 0.48
1–2 years 61 14 887 4.10
3–5 years 111 25 589 4.34
6–10 years 345 47 951 7.19
11–18 years 402 81 417 4.94
Total 923 178 231 5.18
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another family member but after discussion agreed to register
at a community pharmacy. The number of children with epi-
lepsy and the number of pharmacies in each municipality/
district is shown in Table 2. The number of children with
epilepsy per pharmacy ranged from 0–37.
Carbamazepine was the most widely prescribed AED but
was not available as a suspension (Table 3). Sodium valproate
was the second most frequently prescribed AED but was only
available from community pharmacies as a syrup in a con-
centration of 125 mg/5 ml. The majority of children who
required valproate as a tablet received magnesium valproate.
Most of the AEDs were available from all levels of phar-
macy. The price of a month’s supply of AEDs ranged from
being freely available (sodium valproate suspension and
tablets and topiramate tablets) to 18 Cuban pesos (CUPs)
(vigabatrin) (Table 3). On 24% of occasions an AED was not
Table 2 Demographic information of children with epilepsy and community pharmacies in Camagüey Province, Cuba
Municipalities
Child
population
Number of children
with epilepsy
Total number of
pharmacies
Camagüey
A 18 838 101 7
B 17 261 64 5
C 9 853 92 11
D 24 720 132 12
Florida 15 763 61 17
Esmeralda 7 146 35 8
Vertientes 12 978 62 10
Céspedes 5 956 47 5
Minas 8 926 47 6
Santa Cruz del Sur 12 310 18 13
Jimaguayú 5 548 54 8
Sibanicú 7 552 53 7
Sierra de Cubitas 4 748 20 8
Nuevitas 3 656 71 8
Guáimaro 12 979 53 15
Najasa 3 997 13 9
Total 178 231 923 149
Table 3 Cost and availability of antiepileptic drugs in community pharmacies in Camagüey Province, Cuba
Drug Pharmaceutical formulation
Price for a month’s
supply (Cuban pesos)
Quantities of weeks in which
the AED was out of stock
Number of
children
Carbamazepine E 90 tablets 200 mg E 4.50 0 480
Clonazepam 50 tablets 1 mg 5.30 0 31
Ethosuximide 30 capsules 250 mg† 13.80 0 4
Lamotrigine 30 tablets 100 mg† 12.00 0 10
Phenytoin E 50 chew tablets 50 mg E 1.60 0 0
Phenytoin 230 ml suspension 125 mg/5 ml 6.00 0 37
Phenobarbitone E 60 ml elixir 15 mg/ml E 2.10 0 0
Phenobarbitone E 10 tablets 100 mg E 0.45 4 46
Phenobarbitone E 20 tablets 15 mg E 0.60 0 0
Primidone 10 tablets 0.25 mg 0.90 0 0
Primidone 115 ml suspension 200 mg/ml 1.80 0 0
Topiramate 10 tablets 100 mg† Free‡ 0 7
Magnesium valproate 30 tablets 190 mg 1.00 5 163
Sodium valproate 120 ml syrup 125 mg/5 ml 10.00 2 156
Sodium valproate 120 ml suspension 250 mg/5 ml Free‡ 0 10
Sodium valproate E 100 tablets 500 mg E Free‡ 0 15
Vigabatrin 60 tablets 500 mg 18.00 0 18
Exchange rate of pesos to euros (12/2009): 1 Cuban peso = 0.0551 euro.
† = Imported; ‡ = from hospital pharmacy only; AED, antiepileptic drug; E = essential medicine (onWorld Health Organization List of Essential Medicines
for Children9).
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available at the local pharmacy. Three formulations of AEDs
were not available within the community pharmacies for
between 2 and 5 weeks (Table 3). They were, however, avail-
able in the hospital pharmacies.
Discussion
The estimated prevalence of epilepsy in children in
Camagüey Province (5.18 per thousand children) is lower
than the prevalence in children and adults throughout Latin
America (12.4)[3] and in Brazilian children living in an area of
high deprivation (8.7).[4] It is, however, similar to the only
previous study (published 30 years ago) looking at the preva-
lence of children with epilepsy in Cuba (7.5).[13]
A limitation of this study is that the prevalence of epilepsy
was estimated by the number of children receiving AEDs.
Others have used questionnaires looking at the entire popula-
tion.[4] Using the number of patients receiving AEDs has pre-
viously been used in countries with good primary health care
(Sweden and Denmark).[1,2] Cuba has an excellent primary
health care system.[11] All children have a family doctor who
routinely sees every child twice a year.[11] This excellent system
of primary health care, alongside integration between
primary and secondary health care ensures that children with
epilepsy are identified.
The low prevalence of epilepsy in Cuba has previously
been noted.[3] In children, contributory factors include:
a comprehensive immunisation schedule; excellent ante-
natal care that is associated with a low prevalence of
low birth weight babies;[14] a low incidence of infectious
diseases such as malaria, tuberculosis, schistosomiasis and
cysticercosis.[15]
The vast majority of the children (94%) were on a single
AED only, which is widely accepted as best clinical practice.
Carbamazepine and valproate were the two most frequently
prescribed AEDs and they are the medicines recommended
as first-line therapy, in both Cuba and the UK.[16] Many
children received magnesium valproate which is not exten-
sively used in Europe. It is, however, widely used in Latin
America and has been shown to have bioequivalence and
similar efficacy to sodium valproate.[17–19] It is considerably
cheaper than sodium valproate and may actually have some
advantages in that there is less inter-individual variation
in plasma concentrations of valproic acid with magnesium
valproate.[17]
Access to medicines is a significant problem in low and
lower-middle income countries. A study of 14 countries in
Central Africa identified a significant lack of essential medi-
cines for children in pharmacies and central medical stores
with availability in retail or private pharmacies ranging from
38–62%.[10] A recent study of epilepsy in Africa found that
30% of the patients with epilepsy and 73% of children never
received treatment.[20]
Access to AEDs in pharmacies in Camagüey is generally
good for a lower-middle income country in that on 76% of
occasions the AED was available. The USA has imposed an
economic blockade on Cuba for the last 50 years, which
makes it more difficult to obtain medicines as well as many
items involved in the transportation of goods.[21]
Three different formulations of valproate and phenobarbi-
tone (sodium valproate syrup, magnesium valproate tablets
and phenobarbitone tablets) were not available for between 2
and 5 weeks in the community pharmacies. All three formu-
lations were, however, available at the hospital pharmacy.
Hospital pharmacies will dispense AEDs free of charge in an
emergency situation, i.e. if the community pharmacy does
not have the AED in stock. The hospitals have enough medi-
cines within their storerooms for at least two months. The
most significant shortage related to magnesium valproate
tablets, which were not available for 5 weeks.
Parents could go to an alternative pharmacy (includ-
ing the hospital pharmacy) if the AED was unavailable or
wait for a maximum of up to 2 days for the pharmacy
to arrange transfer of the appropriate formulation from
another pharmacy within the province. There is a weekly
meeting within the province between the head of pharmacy
and the companies involved in the distribution and storage
of medicines to try and ensure that children continue to
receive treatment.
Despite the successes of ensuring that children receive AED
therapy, there are clearly issues that could be improved. Car-
bamazepine is not available in a liquid formulation. The only
medicines available in a liquid formulation are sodium val-
proate, which is not recommended for children under the age
of 3 years because of the risk of hepatotoxicity and the older
AEDs (phenytoin, phenobarbitone and primidone) all of
which have a higher incidence of side effects. Although health
care itself is free within Cuba, parents still have to pay for
AEDs for their children with epilepsy. The problems in Cuba
in relation to access to AED therapy, however, are minor in
comparison to many other lower middle-income countries
throughout the world. The stigma of epilepsy is a major
problem in many countries.[7] Universal education plays a
major role in combating stigma. As well as combating stigma,
health professionals and health systems need to ensure that
AEDs are readily available at pharmacies that are accessible
and that the AEDs are sold at a price that is affordable to the
majority of the population.
Conclusions
The prevalence of epilepsy in children in Cuba is lower than
that estimated in other lower middle-income countries. It is
possible for lower middle-income countries to ensure that
children with epilepsy receive regular AED therapy.
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